SecBot SecBot
8-K ·Filed Aug 11, 2026

TOVX

Theriva Biologics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed3mo ago SEC0001104659-26-093782
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

This is a routine quarterly update for a pre-revenue clinical-stage biotech with no material financial surprises. The VIRAGE2 dosing and retinoblastoma protocol design are incremental pipeline progress but do not change the fundamental risk/reward. Monitor for FDA feedback on the retinoblastoma protocol (expected Q3 2026) and VIRAGE2 data (Q3 2027). Cash runway into Q1 2027 suggests a financing event is likely within 12 months.

DirectionNeutral
Confidencemedium
Horizonmonths

VCN-01

▲ Bullish Named in this 8-K
Impact
Phase
Phase 2b completed; Phase 2a (VIRAGE2) authorized/enrolling; Phase 3 design aligned with FDA and EMA
Time to market
Likely 4-6 years if Phase 3 is successful, assuming the company secures funding/partnership to initiate a pivotal trial
Next catalyst
None dated

What to watchVCN-01 is the only meaningful asset at a ~$10M market-cap company. The positive VIRAGE Phase 2b data and FDA/EMA alignment on Phase 3 design are real positives, but the company has only ~$14M cash (runway into Q1 2027) and needs a partnership or dilutive financing to fund the pivotal trial. Watch for partnership/licensing announcements and VIRAGE2 interim data as the next catalysts, the stock is highly binary and prone to large swings.

Price Chart

Loading chart...

Executive Summary

Theriva Biologics reported Q2 2026 financial results with a net loss of $3.2M ($0.07/share), compared to a $13.1M loss ($1.93/share) in Q2 2025. The narrower loss was driven by a $9.2M prior-year contingent consideration adjustment that did not recur. Operationally, the company dosed first patients in the VIRAGE2 Phase 2a trial of VCN-01 in metastatic PDAC and completed the design of a Phase 2/3 retinoblastoma trial. Cash burn continues, with $11.3M in cash providing runway into Q1 2027, but no revenue was reported and the company remains a pre-revenue clinical-stage biotech with no near-term catalysts that would change the fundamental valuation story.

Key Financial Metrics

EPS
−$0.07
Revenue
$0.00
Rating
in line

Key Facts

  • First patients dosed in VIRAGE2 Phase 2a trial of VCN-01 in metastatic PDAC; enrollment expected to complete H2 2026 with data by Q3 2027.
  • Cash and cash equivalents of $11.3M as of June 30, 2026, down from $13.1M at Dec 31, 2025; cash runway into Q1 2027.
  • Net loss of $3.2M ($0.07/share) for Q2 2026 vs $13.1M ($1.93/share) in Q2 2025; prior year included $9.2M contingent consideration adjustment.
  • No revenue reported for Q2 2026; $300K license revenue recognized in Q1 2026.
  • Completed design of proposed Phase 2/3 clinical trial of VCN-01 in retinoblastoma; plan to discuss protocol with FDA in Q3 2026.

Financial Impact

Cash burn of $1.7M from Dec 31, 2025 to June 30, 2026; net loss of $5.3M for H1 2026

cashnet lossoperating expenses

Risk Factors

  • Cash runway only into Q1 2027; likely need for dilutive financing within 12 months.
  • All pipeline candidates are pre-commercialization; no approved products or revenue stream.
  • VIRAGE2 is a 6-patient single-arm trial; results may not support Phase 3 design as hoped.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-093782
Document: tm2622636d1_8k.htm0001104659-26-093782
Document: 0001104659-26-093782-index-headers.html0001104659-26-093782
Document: 0001104659-26-093782-index.html0001104659-26-093782
Document: 0001104659-26-093782.txt0001104659-26-093782
8-K Data (Synthetic)0001104659-26-093782

Track record

11 reports on TOVX

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +17.39% at T+60 after the Aug 4, 2026 report. 3 of 5 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.1600 to $0.1441 Now $0.1400 −12.50% ▼ −9.94% −9.57% vs SPY
  2. Nov 2, 202614d ago 8-K Neutral 5/10 Entry $0.1820 to $0.1900 Now $0.1400 −23.08% ▲ +4.40% +2.74% vs SPY
  3. Oct 20, 202627d ago DEF 14A Bearish 5/10 Entry $0.1966 to $0.1900 Now $0.1400 +28.79% ▲ +3.36% +2.18% vs SPY
  4. Aug 11, 202613w ago 8-K Neutral 4/10 Viewing No price data
  5. Aug 11, 202613w ago Press Release Neutral 5/10 Entry $0.2300 to $0.2400 Now $0.1400 −39.13% ▲ +4.35% +4.10% vs SPY
  6. Aug 4, 202614w ago 8-K Bearish 4/10 Entry $0.2300 to $0.2251 Now $0.1400 +39.13% ▲ +2.13% +1.93% vs SPY
  7. Jul 7, 202618w ago 8-K Bullish 5/10 Entry $0.2354 to $0.2378 Now $0.1400 −40.53% ▲ +1.02% +1.33% vs SPY
  8. Jun 11, 202622w ago Press Release Bullish 7/10 Entry $0.3070 to $0.3038 Now $0.1400 −54.40% ▼ −1.04% −1.58% vs SPY
  9. Apr 17, 202630w ago 8-K Bullish 7/10 Entry $0.4100 to $0.3400 Now $0.1400 −65.85% ▼ −17.07% −16.42% vs SPY
  10. Mar 12, 202635w ago 8-K Mixed 6/10 Entry $0.1800 to $0.1800 Now $0.1400 −22.22% · 0.00% +0.60% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 5h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 11, 2026